Beyondspring (BYSI) Stock
Cancer drug developer testing treatments in clinical trials. Here's the price, business snapshot, and what's worth knowing about Beyondspring in October 2026.
BeyondSpring Inc (BYSI) is a small-cap, clinical-stage biotechnology company focused on oncology drug development. With a market capitalisation of about $88.71 million, the company’s near-term progress is driven largely by clinical trial readouts, regulatory interactions and potential collaborations or licensing deals. Investors should be aware that outcomes hinge on trial data and approvals, making the share price potentially volatile. As a development-stage business, BeyondSpring may require additional financing, which can dilute shareholders. This summary is for general educational purposes only and not personalised investment advice. The stock may suit investors with a higher risk tolerance who understand biotech-specific risks; values can rise or fall and past performance does not predict future results.
Beyondspring (BYSI) Stock Forecast
Analyst price target, next 12 months
$1.25
+106.4% vs today's $0.61
Price range over the last 12 months
Close to its 12-month low
Analysts covering Beyondspring have a consensus 12-month target of $1.25, above the current price of $0.61.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 1 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying BeyondSpring's stock with a target price of $1.25, indicating growth potential.
Financial Health
BeyondSpring is generating a modest amount of cash flow per share, indicating stable financial activity.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical-stage pipeline
Trial readouts and regulatory progress are central to valuation; results can be binary and may cause significant share movement.
Potential catalysts
Upcoming study results, approvals or partnerships could change the outlook, though timings and outcomes are uncertain.
Small-cap dynamics
Lower market capitalisation can create higher volatility and liquidity constraints; suitable for investors who accept greater risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
